Miracor's PICSO coronary sinus occlusion system treats the 1st U.K. large acute heart attack patient following a CE Mark win in the European Union.

Private medical device maker Miracor Medical Systems GmbH won CE Mark approval for its Pressure-controlled Intermittent Coronary Sinus Occlusion System.
In conjunction with the regulatory win, the company announced that it successfully treated its 1st patient, a U.K. woman who suffered a large acute heart attack.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...